Amphastar Pharmaceuticals Q3 2026 Results: Net Income $37.8M, Up 117.7% YoY
Amphastar Pharmaceuticals reported total assets of $1.71 billion as of September 30, 2026, up from $1.63 billion at year-end 2025. The company maintained a strong liquidity position with $204.6 million in cash and cash equivalents, while total liabilities increased to $897.2 million, primarily driven by long-term debt and operating lease liabilities.
- Key figure
- Net income $37.8M · +117.7% YoY